HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Verma on the Future of HER2-Positive Breast Cancer

March 8th 2014

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, provides an outlook on the treatment of HER2-positive breast cancer.

Blackwell Explores Emerging Trends in Treating HER2 Metastatic Breast Cancer

March 7th 2014

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.

Conclusion: Future Direction of Breast Cancer Treatment

January 22nd 2014

Preventing Skeletal-Related Events in Breast Cancer

January 22nd 2014

Chemotherapeutics in Metastatic Breast Cancer

January 22nd 2014

CDK4/6 Inhibitors in Metastatic Breast Cancer

January 22nd 2014

Next Steps for Everolimus in Metastatic Breast Cancer

January 22nd 2014

Upfront Treatment of HR-Positive MBC

January 22nd 2014

Case Study: HER2-Positive Oligometastatic Breast Cancer

January 22nd 2014

Phase III Clinical Trials in HER2-Positive Breast Cancer

January 22nd 2014

Novel Drug Development in Breast Cancer

January 22nd 2014

Role of Lapatinib in HER2-Positive Breast Cancer

January 22nd 2014

Recommendations for Optimal HER2 Testing in Breast Cancer

January 22nd 2014

T-DM1 in HER2-Positive Metastatic Breast Cancer

January 22nd 2014

PIK3CA Mutations in HER2-Positive Breast Cancer

January 22nd 2014

Frontline Pertuzumab for Metastatic Breast Cancer

January 22nd 2014

Treating Low-Risk HER2-Positive Breast Cancer

January 22nd 2014

Overview of HER2-Targeted Therapies in Breast Cancer

January 22nd 2014

Gradishar Provides Insight into New Breast Cancer Treatments

January 21st 2014

New treatments for HER2-positive (HER2+) tumors have dominated media coverage of breast cancer breakthroughs over the past year, but William Gradishar sees promise on many fronts.

BOLERO-3 Safety Analysis Finds Everolimus Regimen Is Manageable

December 13th 2013

The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.